Combination of a histone deacetylase inhibitor with a death receptor ligand

Details for Australian Patent Application No. 2004271730 (hide)

Owner Novartis AG University of South Florida Board of Trustees

Inventors Bhalla, Kapil N.; Atadja, Peter Wisdom

Agent Davies Collison Cave

Pub. Number AU-A-2004271730

PCT Pub. Number WO2005/025619

Priority 60/504,655 18.09.03 US

Filing date 17 September 2004

Wipo publication date 24 March 2005

International Classifications

A61K 45/06 (2006.01) Medicinal preparations containing active ingredients not provided for in groups

A61P 35/00 (2006.01) Antineoplastic agents

Event Publications

16 March 2006 PCT application entered the National Phase

  PCT publication WO2005/025619 Priority application(s): WO2005/025619

25 September 2008 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This application lapsed under section 142(2)(e). Examination has been requested or an examination report has issued for this application. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2004271731-Pharmaceutical products comprising bisphosphonates

2004271726-Improvements in vaccination